Targeted therapeutic strategies in malignant melanoma

Drug Discovery Today: Disease Mechanisms

Volumn 5, Issue 1, 2008, Pages

  Dietrich, Sascha ^a   Kasper, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; CARBOPLATIN; DACARBAZINE; INTERLEUKIN 2; IPILIMUMAB; LENALIDOMIDE; OBLIMERSEN; PACLITAXEL; PLACEBO; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TICILIMUMAB;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTISENSE THERAPY; BRAIN METASTASIS; CANCER REGRESSION; CLINICAL TRIAL; COLITIS; DEEP VEIN THROMBOSIS; DERMATITIS; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPOPHYSITIS; IMMUNOMODULATION; LOW DRUG DOSE; LUNG EMBOLISM; MELANOMA; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOSIS; TUMOR IMMUNITY; TUMOR NECROSIS; TUMOR REGRESSION;

EID: 67349106152     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.04.008     Document Type: Review

References (53)

1. Armstrong B.K., and Kricker A. Cutaneous melanoma. Cancer Surv. 19-20 (1994) 219-240
2. Ahmed I. Malignant melanoma: prognostic indicators. Mayo Clin. Proc. 72 (1997) 356-361
3. Garbe C., et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75 (1995) 2484-2491
4. Miller B., et al. Cancer Statistics Review: 1973-1989 (1992), US Department of Health and Human Services pp. 92-278
5. Barth A., et al. Prognostic factors in 1.521 melanoma patients with distant metastases. J. Am. Coll. Surg. 181 (1995) 193-201
6. Balch C.M., et al. Prognostic factors analysis of 17,600 melanoma patients, validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19 (2001) 3622-3634
7. Guerry D., and Schuchter L.M. Disseminated melanoma: is there a new standard therapy?. N. Engl. J. Med. 327 (1992) 560-561
8. Schadendorf D. Is there a standard for the palliative treatment of melanoma?. Onkologie 25 (2002) 74-76
9. Eigentler T.K., et al. Palliative therapy of disseminated malignant melanoma: a systemic review of 41 randomised clinical trials. Lancet Oncol. 4 (2003) 748-759
10. Tarhini A.A., and Agarwala S.S. Novel agents in development for treatment of melanoma. Expert Opin. Investig. Drugs 14 (2005) 885-892
11. Kaufmann R., et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J. Clin. Oncol. 23 (2005) 9001-9007
12. D'Amato R.J., et al. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. 91 (1994) 4082-4085
13. Keifer J.A., et al. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J. Biol. Chem. 276 (2001) 22382-22387
14. Marriott J.B., et al. Thalidomide and its analogous have distinct and opposing effects on TNF-α and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells. Clin. Exp. Immunol. 130 (2002) 75-84
15. Reiriz A.B., et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res. 14 (2004) 527-531
16. Pawlak W.Z., and Legha S.S. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res. 14 (2004) 57-62
17. Hwu W.J., et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. 21 (2003) 3351-3356
18. Danson S., et al. Randomized phase II study of temozolomide given every 8 h or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J. Clin. Oncol. 21 (2003) 2551-2557
19. Hwu W.J., et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103 (2005) 2590-2597
20. Krown S.E., et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107 (2006) 1883-1890
21. Bartlett J.B., et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer 90 (2004) 955-961
22. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 64 (2005) 671-680
23. Varker K.A., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol. 14 (2007) 2367-2376
24. Korsmeyer S.J. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 59 (1999) 1693-1700
25. Jansen B., et al. Bcl-2 antisense therapy chemosensitizes melanoma in SCID mice. Nat. Med. 4 (1998) 232-234
26. Miller A., et al. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res. 64 (2004) 509
27. Jansen B., et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356 (2000) 1728-1733
28. Piro L.D. Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology 18 (2004) 5-10
29. Stein C.A., et al. Antisense strategies for oncogene inactivation. Semin. Oncol. 32 (2005) 563-572
30. Danson S., and Lorigan P. Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs 65 (2005) 733-743
31. Ugurel S., and Schadendorf D. Systemic treatment in advanced melanoma: innovative perspectives. Onkologie 26 (2003) 234-238
32. Demunter A., et al. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 61 (2001) 4916-4922
33. Gray-Schopfer V.C., et al. The role of B-RAF in melanoma. Cancer Metast. Rev. 24 (2005) 165-183
34. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
35. Solit D.B., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
36. Curtin J.A., et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353 (2005) 2135-2147
37. Wilhelm S.M., et al. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
38. Strumberg D., et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY-43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23 (2005) 695-972
39. Eisen T., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br. J. Cancer 95 (2006) 581-586
40. Flaherty K., et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol. 22 (2004) 711
41. Molhoek K.R., et al. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J. Transl. Med. 3 (2005) 39
42. Flaherty K.T. New molecular targets in melanoma. Curr. Opin. Oncol. 16 (2004) 150-154
43. Kapadia D., and Fong L. CTLA-4 blockade: autoimmunity as treatment. J. Clin. Oncol. 23 (2005) 8926-8928
44. Chambers C.A., et al. CTLA-4 mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19 (2001) 565-594
45. Tivol E.A., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995) 541-547
46. Leach D., et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996) 1734-1736
47. Hurwitz A.A., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60 (2000) 2444-2448
48. Tchekmeddyian S., et al. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. J. Clin. Oncol. 21 (2002) 21 abstract 74
49. Hodi F.S., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4712-4717
50. Attia P., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23 (2005) 6043-6053
51. Maker A.V., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12 (2005) 1005-1016
52. Sanderson K., et al. Autoimmunity in a phase I trial of fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23 (2005) 741-750
53. Ribas A., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte associate antigen-4 monoclonal antibody CP-675206. J. Clin. Oncol. 23 (2005) 8968-8977